Conquering Convenience: BofA’s Erica Racks Up 2B Interactions
Bank of America's virtual assistant, Erica, has had over 2 billion interactions with 42 million clients since its 2018 launch, providing personalized guidance and insights.
Bank Of America Sees Gold At $3,000, Warns Of A Copper Supply Crisis: Metals ‘Dance To Their Own Tune’
Gold prices projected to jump to $3,000/oz by 2025 due to strong demand from central banks and investors returning to market with Fed rate cuts.
Salesforce & IQVIA Expand Partnership: Life Sciences Cloud Gets A Superpower Boost
Salesforce shares rise after partnership with IQVIA to develop Life Sciences Cloud for customer engagement.
AI Could Consume 25% Of US Power By 2030: ‘The More Information They Gather… The More Power It Takes,’ Warns Arm CEO
AI data centers could consume 25% of U.S. power by 2030, Arm and SoftBank invest $25M in research to reduce energy use and combat China's tech dominance.
Adios Argentina: HSBC Divests Banking Operations In Argentina For $550M
HSBC's subsidiary, HSBC Latin America B.V., sells Argentina business to Grupo Financiero Galicia for $550 million, focusing on higher value opportunities.
Chevron Exits Myanmar’s Yadana Gas Field: Report
Chevron Corp. has left Yadana gas field in Myanmar over human rights concerns, after redistributing stake to remaining shareholders.
Suncor Pays C$390K Penalty For Worker Death: Details
Syncrude Canada, a majority-owned oil sands producer by Suncor Energy Inc., will reportedly pay C$390,000 after pleading guilty to a health and safety charge.
What’s Going On With BP Shares Premarket Today?
BP shares rise after reporting Q1 2024 update with higher upstream production expected, but also potential impact from lower gas prices.
Analysts Express Confidence in Alnylam’s Hypertension Drug Despite Mixed Trial Data
The latest findings from Alnylam Pharmaceuticals' KARDIA-2 Phase 2 study are on zilebesiran's efficacy and safety in treating hypertension. Results show significant reductions in systolic blood pressure with standard-of-care antihypertensives.
Johnson & Johnson’s Carvykti Stands Ahead Of Bristol Myers’ Rival Blood Cancer Therapy With FDA Approval For Wider Population
FDA approves Johnson & Johnson's Carvykti, a BCMA-targeted therapy for relapsed or refractory multiple myeloma patients, offering hope with increased manufacturing capacity and extended collaboration efforts.